INBS reports prelim Q2 revenue ~$0.61M; gross margin up to 38.5%; FDA 510(k) submitted for U.S. market entry in 2025

INTELLIGENT BIO SOLUTIONS INC.

Preliminary Q2 FY2025 revenue ~$0.61M; 6-month revenue ~$1.48M; gross profit margin improved to 38.5% from 27.7%.
Fiscal year 2024 revenues grew 148% YoY; over 400 accounts in 19 countries with customer employee base ~1.4M.
Submitted 510(k) pre-market notification to FDA in Dec 2024; on track for U.S. market entry in 2025.
PK study showed fingerprint sweat correlates with blood at 95% confidence; Method Comparison Study showed ~94% accuracy.
Gross profit up 32.6% to $0.57M for six months; strategic focus on higher-margin cartridge sales driving margin expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.